The Foundation of the Carlo Besta Neurological Institute, is, under Italian Civil Law, a “Foundation of Participation,” in which representatives within the Board of Governors play a prominent role. Members of the Board of Governors include representatives of the Italian Ministry of Health, the Region of Lombardy, and the Municipality of Milan − all of which are Founders of the Besta Foundation.
The organs of the Besta Foundation are the President, the Board of Governors, the General Manager, the Scientific Director, and the Board of Auditors.
The Carlo Besta Neurological Institute, first established in 1918, was designated by the Italian government as an Institute of Research and Treatment (IRCCS) in 1981. On July 15, 2006 the Institute transformed into the Foundation of the Carlo Besta Neurological Institute, IRCCS, in accordance with Italian Legislative Decree No. 288 of 2003. The activity of the Foundation is governed by its Statute approved by Italian Ministry of Health, April 28, 2006.
The Foundation of the Carlo Besta Neurological Institute, IRCCS, is a regional and national centre of excellence for the treatment of neurological diseases, and also undertakes research aimed to improve the diagnosis and treatment of these diseases. The Foundation treats oncological, degenerative and rare neurological diseases affecting both children and adults, and is highly active in the field of neurosurgery. It is a regional and national referral centre for several specific neurological conditions.
The fundamental aims of the Foundation are to provide high quality, ethical and efficient care and treatment to its patients, making use of the results of it own research and that of others, always putting the interests of patient first. In fulfilment of these aims, the Foundation provides care and treatment to patients, carries out clinical and basic research to improve treatment and diagnosis (translational research), provides professional training and educational programmes (including those for pre and postgraduate university students) and develops new managerial techniques to improve health care provision and research efficiency.
Contact
Via Celoria 11, 20133 Milano (Italy)
Tel. +39 02.23941 – Fax +39 02.70638217
Presidente
Carlo Borsani
tel. 02.26684954
fax 02.2394.2980
Direttore Generale
Giuseppe De Leo
tel. 02.2394.2310
fax 02.2394.2531
e-mail dirgen@istituto-besta.it
Direttore Scientifico
Ferdinando Cornelio
tel. 02.2394.2335
fax 02.2363973
e-mail dirsci@istituto-besta.it
Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in Italy, the nature of the institute’s collaboration with the…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
